TSC2 and kidney neoplasm: Here, we explore the potential benefit of the mTORC1 inhibitor RAD001 (everolimus) in comparison to a dual pan-class I PI3K/mTOR catalytic inhibitor NVP-BEZ-235 [13] in the therapy of Tsc2 mouse kidney tumors.